Atovaquone
Small molecule targets STAT3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MEPRON | — | 1999-01-05 | fda.gov ↗ |
| Approved | US (FDA) | MEPRON | — | 1992-11-25 | fda.gov ↗ |
Trials 28 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06294912 Background | Apr 2024 → Jan 2025 | malaria | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04568772 Background | Nov 2020 → Jul 2021 | gastroesophageal reflux disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02858817 Background | Nov 2016 → Nov 2017 | malaria | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1 | NCT02450578 Comparator | Oct 2015 → Apr 2016 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01858831 Comparator | Apr → May 2012 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02836002 Background | Jun 2016 → Jun 2017 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01442168 Comparator | Sep 2011 → Sep 2013 | Plasmodium falciparum malaria | Modus Therapeutics AB | Terminated | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02297477 Comparator | Dec 2014 → Dec 2015 | Plasmodium falciparum malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Unknown | No outcome recorded |
| Phase 4 | NCT01150344 Comparator | Jul 2010 → Apr 2014 | malaria | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00636935 Background | Feb 2008 → Aug 2013 | pneumocystosis | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00444106 Comparator | May 2007 → Nov 2008 | Plasmodium falciparum malaria | Novartis | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT04203186 Comparator | Mar 2020 → Jun 2021 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded |
| — | NCT03813108 Background | Apr 2019 → Feb 2021 | Plasmodium falciparum malaria | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT03454048 Background | May → Nov 2018 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT02080026 Background | Jun 2014 → Jul 2015 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01660854 Background | Jul 2012 → Jan 2013 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 47 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atovaquone | “Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.
Other Name: atovaquone/proguanil” NCT01660854 ↗44“Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days” NCT04456153 ↗ “antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone)” NCT00636935 ↗ “Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.” NCT04002687 ↗ “250 mg atovaquone, 100 mg proguanil hydrochloride” NCT02450578 ↗ “Atovaquone 500 mg + Proguanil 348 mg” NCT04866602 ↗ “Atovaquone” NCT00984256 ↗ |
| Known as | 566C | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Known as | 566C80 | “To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who...” NCT00001996 ↗5“To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim...” NCT00001991 ↗ “To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii...” NCT00000655 ↗ “Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children” NCT00000773 ↗ “To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis.” NCT00001994 ↗ “atovaquone (566C80)” NCT00001990 ↗ |
| Known as | Atovacuona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Known as | Atovaquone component of malarone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Known as | Atovaquone component of malarone pediatric | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Known as | ATV | “Atoguanil™ is a novel complex of atovaquone (ATV) and proguanil (PG) with enhanced ATV bioavailability compared to Malarone®.” PMID 38918235 ↗ Jun 20241“Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.” NCT04002687 ↗ |
| Known as | m-Atovaquone | “Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children” NCT00000773 ↗ |
| Known as | Mepron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Known as | NSC-759582 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Known as | Wellvone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1450 ↗ |
| Action | Inhibit | “the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC” PMID 34964932 ↗ Dec 2021 |
| Modality | Small molecule | — CHEMBL1450 ↗ |
| Route | Oral | “Oral 566C80” NCT00001990 ↗ |
| Target | STAT3 | “To quantitate the on-target STAT3 inhibitory effect of atovaquone on STAT3-dependent gene transcription.” NCT05998135 ↗ |